![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
L Nie, H Mogami, M Kanzaki, H Shibata and I Kojima
Department of Cell Biology, Gunma University, Maebashi, Japan.
The present study was conducted to establish a pharmacological method of controlling growth of vascular smooth muscle cells (VSMC) by blocking calcium entry. In cultured rat VSMC, 1 nM platelet-derived growth factor (PDGF) induced a biphasic elevation of cytoplasmic free calcium concentration, ([Ca2+]c). The second sustained phase of [Ca2+]c was dependent on extracellular calcium. At lower concentrations, PDGF induced oscillatory changes in [Ca2+]c, and reduction of extracellular calcium attenuated the oscillation. An antiallergic compound, tranilast, abolished the sustained phase of [Ca2+]c induced by 1 nM PDGF. Tranilast also inhibited the oscillatory changes in [Ca2+]c induced by 200 pM PDGF. In addition, PDGF-induced calcium influx in the late G1 phase, as assessed by measuring the initial uptake of 45Ca, was inhibited by tranilast in a concentration-dependent manner. Tranilast also inhibited PDGF-augmented DNA synthesis; the ID50 for the inhibition of DNA synthesis was nearly identical to that for calcium influx. Although tranilast blocked PDGF-induced calcium entry, it did not affect PDGF-mediated autophosphorylation of the PDGF receptor, activation of phosphatidylinositol 3-kinase, activation of Ras or mitogen-activated protein kinase. Similarly, PDGF-induced elevation of diacylglycerol was not affected by tranilast. These results suggest that the antiallergic drug tranilast inhibits PDGF-induced DNA synthesis by blocking PDGF-mediated calcium entry. Tranilast may be of use in controlling PDGF-induced DNA synthesis in VSMC.
This article has been cited by other articles:
|
|
 |
|
  H. Shime, M. Kariya, A. Orii, C. Momma, T. Kanamori, K. Fukuhara, T. Kusakari, Y. Tsuruta, K. Takakura, T. Nikaido, et al. Tranilast Inhibits the Proliferation of Uterine Leiomyoma Cells in Vitro through G1 Arrest Associated with the Induction of p21waf1 and p53 J. Clin. Endocrinol. Metab., December 1, 2002; 87(12): 5610 - 5617. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Spiecker, I. Lorenz, N. Marx, and H. Darius Tranilast Inhibits Cytokine-Induced Nuclear Factor kappa B Activation in Vascular Endothelial Cells Mol. Pharmacol., October 1, 2002; 62(4): 856 - 863. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. A. Capper, A. K. Roshak, B. J. Bolognese, P. L. Podolin, T. Smith, D. L. Dewitt, K. M. Anderson, and L. A. Marshall Modulation of Human Monocyte Activities by Tranilast, SB 252218, a Compound Demonstrating Efficacy in Restenosis J. Pharmacol. Exp. Ther., December 1, 2000; 295(3): 1061 - 1069. [Abstract] [Full Text]
|
|
|
|
 |
|
 A. Takahashi, T. Taniguchi, Y. Ishikawa, and M. Yokoyama Tranilast Inhibits Vascular Smooth Muscle Cell Growth and Intimal Hyperplasia by Induction of p21waf1/cip1/sdi1 and p53 Circ. Res., March 19, 1999; 84(5): 543 - 550. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Nie, M. Kanzaki, H. Shibata, and I. Kojima Activation of Calcium-Permeable Cation Channel by Insulin in Chinese Hamster Ovary Cells Expressing Human Insulin Receptors Endocrinology, January 1, 1998; 139(1): 179 - 188. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. S. Stevenson, M. F. Gomez, D. C. Hill-Eubanks, and M. T. Nelson NFAT4 Movement in Native Smooth Muscle. A ROLE FOR DIFFERENTIAL Ca2+ SIGNALING J. Biol. Chem., April 27, 2001; 276(18): 15018 - 15024. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
